Program

October 6, 2022

3.00 - 4.00 pm	Registration, Poster set-up and welcome coffee
Opening Session
4.00 - 4.15 pm	Welcome by Chairs P. Lampertico and H. Wedemeyer
Session 1 - Virology and Pathogenesis Moderators: M. Dandri and H. Wedemeyer
4.15 - 4.35 pm	The HDV virus: the challenge S. Urban
4.35 - 4.55 pm	Pathogenesis of HDV: new insights J. Lucifora
4.55 - 5.15 pm	Immunology of HDV in untreated and treated patients H. Kefalakes
5.15 - 5.30 pm	Discussion
Session 2 - Epidemiology and Diagnosis Moderators: F. Caruntu and R. Gish
5.30 - 5.50 pm	Epidemiology of HDV: from low to high endemic countries S. Hamid
5.50 - 6.10 pm	Epidemiology of HDV in North America: a forgotten disease? N. Reau
6.10 - 6.30 pm	Diagnosis of HDV: clinical virology and new HBV biomarkers M. Brunetto
6.30 - 6.45 pm	Discussion
6.45 - 7.25 pm	KEYNOTE LECTURE From HDV discovery to perspectives of cure Moderators: P. Lampertico and H. Wedemeyer Speaker: M. Rizzetto
7.25 - 8.15 pm	Apero and DZIF Poster Session
8.15 - 10.30 pm	Dinner

October 7, 2022

8.00 - 8.30 am	Welcome breakfast
8.30 - 8.45 am	Opening remarks Day 2 P. Lampertico and H. Wedemeyer
Session 3 - Diagnosis and Natural History Moderators: P. Lampertico and N. Reau
8.45 - 9.05 am	Non-invasive markers of fibrosis in CHD: pros and cons L. Castera
9.05 - 9.25 am	Natural history of untreated HDV patients: always a progressive disease? S. Aleman
9.25 - 9.45 am	Endpoints of HDV therapy M. Buti
9.45 - 10.10 am	Discussion
10.10 - 10.40 am	Coffee Break and DZIF Poster Session
Session 4 - Antiviral Treatment I Moderators: M. Cornberg and D. Roulot
10.40 - 11.00 am	Peginterferon therapy: effectiveness, predictors, and long-term outcomes T. Asselah
11.00 - 11.20 am	Bulevirtide with or without peginterferon alfa: clinical trials H. Wedemeyer
11.20 - 11.50 am	Bulevirtide with or without peginterferon alfa: real-world studies P. Lampertico
11.50 - 12.15 am	Discussion
12.15 - 1.30 pm	Lunch Break and DZIF Poster Session
Session 5 - Antiviral Treatment II Moderators: K. Agarwal and V. de Lédinghen
1.30 - 1.50 pm	Lonafarnib with or without peginterferon alpha/lambda C. Yurdaydin
1.50 - 2.10 pm	Anti-HBV drugs targeting HBsAg F. Zoulim
2.10 - 2.30 pm	Discussion
Session 6 - Round Table Discussion Moderators: P. Lampertico and H. Wedemeyer
2.30 - 3.45 pm	Hot topics in HDV management. Academia, Pharma and Diagnostics representatives
	- For Academia: S. Aleman, V. de Lédinghen, N. Reau, F. Zoulim - For Pharma and Diagnostics: M. Biermer, I. Choong, G. Cloherty, J.F. Flaherty, C. Hwang, A. Reinhardt, C. Simon
3.45 - 4.00 pm	Closing remarks P. Lampertico and H. Wedemeyer